Fierce Pharma May 3, 2024
ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, there is an ongoing global shortage of BCG.
Now, the California biotech has partnered with the Serum Institute of India in an exclusive deal to manufacture BCG globally.
The arrangement aims to create “a long-term solution to chronic BCG supply shortage issues” and produce BCG “at large scale” for use in combination with Anktiva in non-muscle invasive bladder cancer (NMIBC), ImmunityBio said Thursday.
BCG, originally developed as a tuberculosis vaccine, is also a standard treatment for NMIBC, which accounts for about 80% of around 80,000 new bladder cancer diagnoses each year...
Today's Sponsors
Today's Sponsor